Royalty Pharma Research and Development Expenses 2019-2024 | RPRX

Royalty Pharma research and development expenses for the twelve months ending December 31, 2024 were $2M, a 96.15% decline year-over-year.

  • Royalty Pharma annual research and development expenses for 2024 were $0.002B, a 96.15% decline from 2023.
  • Royalty Pharma annual research and development expenses for 2023 were $0.052B, a 70.64% decline from 2022.
  • Royalty Pharma annual research and development expenses for 2022 were $0.177B, a 11.48% decline from 2021.

Royalty Pharma Research and Development Expenses 2019-2024 | RPRX

  • Royalty Pharma annual research and development expenses for 2024 were $0.002B, a 96.15% decline from 2023.
  • Royalty Pharma annual research and development expenses for 2023 were $0.052B, a 70.64% decline from 2022.
  • Royalty Pharma annual research and development expenses for 2022 were $0.177B, a 11.48% decline from 2021.
Related Stocks
Company NameMarket
Cap
American Express (AXP)$217.7B
Blackstone (BX)$120.5B
Moody's (MCO)$93.5B
Coinbase Global (COIN)$64.8B
Brookfield Asset Management (BAM)$26.9B
Synchrony Financial (SYF)$25.5B
Orix Corp Ads (IX)$24.6B
SoFi Technologies (SOFI)$17.6B
Equitable Holdings (EQH)$17.4B
Jefferies Financial Group (JEF)$14.3B
BB Seguridade Participacoes SA (BBSEY)$14B
Houlihan Lokey (HLI)$12.8B
Globe Life (GL)$10.4B
Daiwa Securities Group (DSEEY)$9.8B
Freedom Holding (FRHC)$9.5B
Brookfield Wealth Solutions (BNT)$8.8B
XP (XP)$8.1B
SouthState (SSB)$7.8B
Upstart Holdings (UPST)$7.8B
StepStone Group (STEP)$7.3B
Rithm Capital (RITM)$6.2B
Blue Owl Capital (OBDC)$6.1B
Lazard (LAZ)$6.1B
Virtu Financial (VIRT)$5.9B
Euronet Worldwide (EEFT)$4.8B
PJT Partners (PJT)$4.2B
AXOS FINANCIAL, INC (AX)$4B
StoneX Group (SNEX)$4B
Intercorp Financial Services (IFS)$3.7B
Abrdn (SLFPY)$3.6B